Pitavastatin: Protection against neuronal retinal damage induced by ischemia-reperfusion injury in rats

Current Eye Research

Volumn 32, Issue 11, 2007, Pages 991-997

  Kawaji, Takahiro ^a   Inomata, Yasuya ^a   Takano, Akiomi ^a   Sagara, Nina ^a   Inatani, Masaru ^a   Fukushima, Mikiko ^a   Tanihara, Hidenobu ^a   Honjo, Megumi ^b  

^a KUMAMOTO UNIVERSITY   (Japan)

^b Kitano Hospital   (Japan)

Author keywords

Ischemia reperfusion injury; Ischemic retinal disease; Neuroprotection; Pitavastatin

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; PADGEM PROTEIN; PITAVASTATIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; INTRAOCULAR HYPERTENSION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY; RETINA INJURY;

ANIMALS; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INJECTIONS, INTRAVENOUS; INTERCELLULAR ADHESION MOLECULE-1; MALE; NEUROPROTECTIVE AGENTS; P-SELECTIN; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY; RETINAL DISEASES; RETINAL GANGLION CELLS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS;

EID: 36248972664     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.1080/02713680701649603     Document Type: Article

References (25)

1. The Scandinavian Simvastatin Survival Study (4S). .Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet. 1994;344:1383-1389.
2. Shepherd J. Statin therapy in clinical practice: new developments. Curr Opin Lipidol. 1995;6:254-255.
3. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 1995;332:481-487.
4. Delanty N, Vaughan CJ. Vascular effects of statins in stroke. Stroke. 1997;28:2315-2320.
5. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med. 1996;335:1001-1009.
6. Baghdasarian SB, Jneid H, Hoogwerf BJ. Association of dyslipidemia and effects of statins on nonmacrovascular diseases. Clin Ther. 2004;26:337-351.
7. Wilson HL, Schwartz DM, Bhatt HR, et al. Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration. Am J Ophthalmol. 2004;137:615-624.
8. Klein R, Klein BE, Tomany SC, et al. Relation of statin use to the 5-year incidence and progression of age-related maculopathy. Arch Ophthalmol. 2003;121:1151-1155.
9. McGwin G, Jr., Owsley C, Curcio CA, Crain RJ. The association between statin use and age related maculopathy. Br J Ophthalmol. 2003;87:1121-1125.
10. McGwin G, Jr, McNeal S, Owsley C, et al. Statins and other cholesterol-lowering medications and the presence of glaucoma. Arch Ophthalmol. 2004;122:822-826.
11. Honjo M, Tanihara H, Nishijima K, et al. Statin inhibits leukocyteendothelial interaction and prevents neuronal death induced by ischemia-reperfusion injury in the rat retina. Arch Ophthalmol. 2002;120:1707-1713.
12. Zambarakji HJ, Nakazawa T, Connolly E, et al. Dose-dependent effect of pitavastatin on VEGF and angiogenesis in a mouse model of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2006;47:2623-2631.
13. Sagara N, Kawaji T, Takano A, et al. Effect of pitavastatin on experimental choroidal neovascularization in rats. Exp Eye Res. 2007;84:1074-1080.
14. Miyahara S, Kiryu J, Yamashiro K, et al. Simvastatin inhibits leukocyte accumulation and vascular permeability in the retinas of rats with streptozotocin-induced diabetes. Am J Pathol. 2004;164:1697-1706.
15. Rosenbaum DM, Rosenbaum PS, Gupta A, et al. Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid. Vision Res. 1997;37:3445-3451.
16. Morizane C, Adachi K, Furutani I, et al. N(omega)-nitro-L-arginine methyl ester protects retinal neurons against N-methyl-D-aspartateinduced neurotoxicity in vivo. Eur J Pharmacol. 1997;328:45-49.
17. Sawada A, Neufeld AH. Confirmation of the rat model of chronic, moderately elevated intraocular pressure. Exp Eye Res. 1999;69:525-531.
18. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA. 1998;279:1643-1650.
19. Laufs U, Liao JK. Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc Med. 2000;10:143-148.
20. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21:1712-1719.
21. Aoki T, Nishimura H, Nakagawa S, et al. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutarylcoenzyme A reductase. Arzneimittelforschung. 1997;47:904-909.
22. Kojima J, Fujino H, Abe H, et al. Identification of metabolites of NK-104, an HMG-CoA reductase inhibitor, in rat, rabbit and dog bile. Biol Pharm Bull. 1999;22:142-150.
23. Kajinami K, Koizumi J, Ueda K, et al. Effects of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia. Hokuriku NK-104 Study Group. Am J Cardiol. 2000;85:178-183.
24. Saito Y, Yamada N, Teramoto T, et al. Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia. Dose-finding study using the double-blind, three-group parallel comparison. Arzneimittelforschung. 2002;52:251-255.
25. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA. 1991;88:4651-4655.